Implementation of Novel AKI Biomarkers in Clinical Practice

Clinical Practice Session

https://www.asn-online.org/education/kidneyweek/2023/program-session-details.aspx?sessId=450414

Session Description

Novel AKI biomarkers have been approved and implemented as diagnostic tests in clinical practice worldwide. This session describes clinicians’ approaches to using these tests to prevent, assess, and manage AKI in clinical practice. They have used AKI biomarkers in different categories, alone or in combination, including kidney stress markers (e.g., TIMP2-IGFBP7); kidney damage markers (e.g., NGAL); kidney dysfunction markers (e.g., serum cystatin C, ultrasound); and US Food and Drug Administration- and European Medicines Agency-supported biomarker panels to detect drug-induced kidney injury during drug development.

Learning Objective(s)

• Discuss approaches to introducing novel AKI biomarkers for clinical use
• Specify the barriers to clinical implementation of novel AKI biomarkers in practice
• Describe approaches to the use of novel biomarkers to prevent, assess, and manage AKI in clinical practice
• Articulate approaches to clinical audit and continuous quality improvement processes related to the implementation of new AKI biomarkers in clinical practice

Learning Pathway(s)

• AKI and Critical Care
• Pharmacology

Moderators

• Rajit K. Basu, MD, MS
• Blaithin A. McMahon, MBChB, PhD